FDA 483 - Pfizer, Inc. - June 28, 2017

An FDA inspection of Pfizer, Inc. in Groton, CT, identified a significant issue regarding the monitoring of clinical studies. The firm failed to ensure that clinical investigators, sub-investigators, and study coordinators completed required protocol training prior to their involvement in studies. This deficiency was observed across multiple clinical sites and involved untimely identification and investigation of missing training.